natural history of type 1 diabetes
DESCRIPTION
PUTATIVE ENVIRONMENTAL TRIGGER. HUMORAL AUTOANTIBODIES. (ICA, IAA, Anti-GAD 65 , IA 2 Ab, etc.). CLINICAL ONSET. Natural History of Type 1 Diabetes. CELLULAR (T CELL) AUTOIMMUNITY. LOSS OF FIRST PHASE INSULIN RESPONSE (IVGTT). BETA CELL MASS. GLUCOSE INTOLERANCE (OGTT). GENETIC - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Natural History of Type 1 Diabetes](https://reader035.vdocuments.site/reader035/viewer/2022062309/568159f3550346895dc73f15/html5/thumbnails/1.jpg)
![Page 2: Natural History of Type 1 Diabetes](https://reader035.vdocuments.site/reader035/viewer/2022062309/568159f3550346895dc73f15/html5/thumbnails/2.jpg)
Natural History of Type 1 DiabetesNatural History of Type 1 Diabetes
CELLULAR (T CELL) AUTOIMMUNITYCELLULAR (T CELL) AUTOIMMUNITY
LOSS OF FIRST PHASE LOSS OF FIRST PHASE INSULIN RESPONSEINSULIN RESPONSE
(IVGTT)(IVGTT)
GLUCOSE INTOLERANCEGLUCOSE INTOLERANCE(OGTT)(OGTT)
HUMORAL AUTOANTIBODIESHUMORAL AUTOANTIBODIES(ICA, IAA, Anti-GAD(ICA, IAA, Anti-GAD6565, IA, IA22Ab, etc.) Ab, etc.)
PUTATIVEPUTATIVEENVIRONMENTALENVIRONMENTAL
TRIGGERTRIGGER
CLINICALCLINICALONSETONSET
TIMETIME
BE
TA
CE
LL
MA
SS
BE
TA
CE
LL
MA
SS
DIABETES
“PRE”-DIABETES
GENETICPREDISPOSITION
INSULITISBETA CELL INJURY
![Page 3: Natural History of Type 1 Diabetes](https://reader035.vdocuments.site/reader035/viewer/2022062309/568159f3550346895dc73f15/html5/thumbnails/3.jpg)
TrialNet Sites – North AmericaTrialNet Sites – North America
![Page 4: Natural History of Type 1 Diabetes](https://reader035.vdocuments.site/reader035/viewer/2022062309/568159f3550346895dc73f15/html5/thumbnails/4.jpg)
TrialNet Sites
![Page 5: Natural History of Type 1 Diabetes](https://reader035.vdocuments.site/reader035/viewer/2022062309/568159f3550346895dc73f15/html5/thumbnails/5.jpg)
TrialNet International SitesTrialNet International Sites
• AustraliaAustralia
• United KingdomUnited Kingdom
• FinlandFinland
• Italy & GermanyItaly & Germany
![Page 6: Natural History of Type 1 Diabetes](https://reader035.vdocuments.site/reader035/viewer/2022062309/568159f3550346895dc73f15/html5/thumbnails/6.jpg)
Immune Tolerance Network
Collaborate on Trials & Mechanistic Assays
Concomitant Review of Protocols
![Page 7: Natural History of Type 1 Diabetes](https://reader035.vdocuments.site/reader035/viewer/2022062309/568159f3550346895dc73f15/html5/thumbnails/7.jpg)
TrialNet GoalsTrialNet Goals
• Explore new therapies in:
– New-onset Type 1 Diabetes
– Relatives “at risk” of Type 1 Diabetes
– High genetic risk individuals
• Further define epidemiology, natural history, and risk factors of Type 1 Diabetes
![Page 8: Natural History of Type 1 Diabetes](https://reader035.vdocuments.site/reader035/viewer/2022062309/568159f3550346895dc73f15/html5/thumbnails/8.jpg)
TIMETIME
Type 1 Diabetes TrialNet StudiesType 1 Diabetes TrialNet StudiesB
ET
A C
EL
L M
AS
SB
ET
A C
EL
L M
AS
S
DIABETES
“PRE”-DIABETES
GENETICPREDISPOSITION
INSULITISBETA CELL INJURY
LOSS OF FIRST PHASE LOSS OF FIRST PHASE INSULIN RESPONSE INSULIN RESPONSE
MULTIPLE ANTIBODY POSITIVEMULTIPLE ANTIBODY POSITIVE
NEWLY DIAGNOSED DIABETES
GENETICALLY AT-RISKGENETICALLY AT-RISK
![Page 9: Natural History of Type 1 Diabetes](https://reader035.vdocuments.site/reader035/viewer/2022062309/568159f3550346895dc73f15/html5/thumbnails/9.jpg)
TrialNet Prevention TrialsTrialNet Prevention Trials
• Relatives at Risk• Current End Point – Development of
Diabetes
• Genetically at Risk Relatives• End Point – Development of
Autoantibodies
![Page 10: Natural History of Type 1 Diabetes](https://reader035.vdocuments.site/reader035/viewer/2022062309/568159f3550346895dc73f15/html5/thumbnails/10.jpg)
![Page 11: Natural History of Type 1 Diabetes](https://reader035.vdocuments.site/reader035/viewer/2022062309/568159f3550346895dc73f15/html5/thumbnails/11.jpg)
DPT-1 ObjectiveDPT-1 Objective
To determine whetherantigen based therapies
(specifically, insulin)of non-diabetic relativescan delay development
of Type 1 diabetes.
![Page 12: Natural History of Type 1 Diabetes](https://reader035.vdocuments.site/reader035/viewer/2022062309/568159f3550346895dc73f15/html5/thumbnails/12.jpg)
DPT·1 Intervention ProtocolsDPT·1 Intervention Protocols
• Parenteral Insulin In Subjects with 5 year Risk of
Type 1 Diabetes > 50%
• Oral Insulin In Subjects with 5 year Risk of
Type 1 Diabetes = 26-50%
![Page 13: Natural History of Type 1 Diabetes](https://reader035.vdocuments.site/reader035/viewer/2022062309/568159f3550346895dc73f15/html5/thumbnails/13.jpg)
DPT·1 Screening ResultsDPT·1 Screening Results
• 103,391 Relatives Screened
• 97,635 Eligible Samples
• 97,273 Samples Analyzed
• 3480 Samples ICA+ (3.58%)
![Page 14: Natural History of Type 1 Diabetes](https://reader035.vdocuments.site/reader035/viewer/2022062309/568159f3550346895dc73f15/html5/thumbnails/14.jpg)
1.01.0
0.90.9
0.80.8
0.70.7
0.60.6
0.50.5
0.40.4
0.30.3
0.20.2
0.10.1
0.00.0
241512415117181718405405378378147147
2229722297140114012972972552559595
1704917049104510452292291921926161
11807118077437431631631301304040
9052905255755711811878783030
74397439457457919149492222
61986198371371666631311616
Number at RiskNumber at Risk
Su
rviv
al D
istr
ibu
tio
n F
un
ctio
nS
urv
ival
Dis
trib
uti
on
Fu
nct
ion
P- Value< 0.001P- Value< 0.001(Log Rank Test)(Log Rank Test)
352435241991993535141488
00 11 22 33 44 55 66 77
Years FollowedYears Followed
STRATA:STRATA: 00 11 22
88
0011223344
33 44
DPT-1 – Time to Diabetes DPT-1 – Time to Diabetes By Number of AntibodiesBy Number of Antibodies
n = 26799
![Page 15: Natural History of Type 1 Diabetes](https://reader035.vdocuments.site/reader035/viewer/2022062309/568159f3550346895dc73f15/html5/thumbnails/15.jpg)
1.01.0
0.90.9
0.80.8
0.70.7
0.60.6
0.50.5
0.40.4
0.30.3
0.20.2
0.10.1
0.00.0
4193341933879879372372339339
3935239352659659344344293293
3241032410527527283283223223
2443424434395395212212156156
19278192782852851561569797
146671466719319377774949
1063110631989835351212
Number at RiskNumber at Risk
Su
rviv
al D
istr
ibu
tio
n F
un
ctio
nS
urv
ival
Dis
trib
uti
on
Fu
nct
ion
P- Value< 0.001P- Value< 0.001(Log Rank Test)(Log Rank Test)
554455441212
44
00 11 22 33 44 55 66 77
Years FollowedYears Followed
STRATA:STRATA: ICA – SubjectsICA – Subjects Not Elig Rand (Staged)Not Elig Rand (Staged)
Rand – OralRand – Oral
88 99
11
ICA – SubjectsICA – SubjectsNot Elig Rand (Staged)Not Elig Rand (Staged)Rand – OralRand – OralRand - ParenteralRand - Parenteral
Rand - ParenteralRand - Parenteral
DPT-1 – Time to Diabetes DPT-1 – Time to Diabetes ICA- vs Staging Outcome ICA- vs Staging Outcome (Parenteral, Oral, Not Eligible)(Parenteral, Oral, Not Eligible)
n = 43523
Oral Insulin Trial
Parenteral Insulin Trial
ICA+ Not Eligible
![Page 16: Natural History of Type 1 Diabetes](https://reader035.vdocuments.site/reader035/viewer/2022062309/568159f3550346895dc73f15/html5/thumbnails/16.jpg)
TIMETIME
Type 1 Diabetes TrialNet StudiesType 1 Diabetes TrialNet StudiesB
ET
A C
EL
L M
AS
SB
ET
A C
EL
L M
AS
S
DIABETES
“PRE”-DIABETES
GENETICPREDISPOSITION
INSULITISBETA CELL INJURY
LOSS OF FIRST PHASE LOSS OF FIRST PHASE INSULIN RESPONSE INSULIN RESPONSE
MULTIPLE ANTIBODY POSITIVEMULTIPLE ANTIBODY POSITIVE
NEWLY DIAGNOSED DIABETES
GENETICALLY AT-RISKGENETICALLY AT-RISK
![Page 17: Natural History of Type 1 Diabetes](https://reader035.vdocuments.site/reader035/viewer/2022062309/568159f3550346895dc73f15/html5/thumbnails/17.jpg)
InsulinInsulin
C-peptide
A chain
B chain
S S
SNH2COOH
![Page 18: Natural History of Type 1 Diabetes](https://reader035.vdocuments.site/reader035/viewer/2022062309/568159f3550346895dc73f15/html5/thumbnails/18.jpg)
TrialNet Intervention TrialsTrialNet Intervention Trials
• Recent Onset Type 1 Diabetes• Current End Point – Preservation of C-
Peptide
• Later Stage Type 1 Diabetes with Preserved C-Peptide
• Potential End Point – Preservation of C-Peptide
![Page 19: Natural History of Type 1 Diabetes](https://reader035.vdocuments.site/reader035/viewer/2022062309/568159f3550346895dc73f15/html5/thumbnails/19.jpg)
Example of Mixed Meal Tolerance TestExample of Mixed Meal Tolerance Test
Active Rx
Placebo
![Page 20: Natural History of Type 1 Diabetes](https://reader035.vdocuments.site/reader035/viewer/2022062309/568159f3550346895dc73f15/html5/thumbnails/20.jpg)
Changes in C-Peptide Responses Changes in C-Peptide Responses During MMTT Over TimeDuring MMTT Over Time
0
20
40
60
80
100
120
140
Baseline 6 months 12 months
C-P
ep
tid
e -
To
tal
AU
C
pm
ol/
ml/
24
0 m
in
Active RxComparison
Herold et al, NEJM 2002; 346:1692
![Page 21: Natural History of Type 1 Diabetes](https://reader035.vdocuments.site/reader035/viewer/2022062309/568159f3550346895dc73f15/html5/thumbnails/21.jpg)
Glucagon Stimulated C-Peptide Over Time Glucagon Stimulated C-Peptide Over Time
Active Rx
Placebo
![Page 22: Natural History of Type 1 Diabetes](https://reader035.vdocuments.site/reader035/viewer/2022062309/568159f3550346895dc73f15/html5/thumbnails/22.jpg)
TrialNet InterventionsTrialNet Interventions• New-Onset Diabetes
– Anti-CD3 (via ITN collaboration)– Mycophenolate Mofetil +/- Anti-CD25– Anti-CD20– Anti-CD3 + Exenatide– IL-2 plus Sirolimus – Phase 1 Safety Study
• Relatives At Risk– Natural History– Oral Insulin– Beta Cell Preservation (exenatide) – pilot study– Anti-CD3
• Newborns– Nutritional : Omega-3-Fatty Acids
![Page 23: Natural History of Type 1 Diabetes](https://reader035.vdocuments.site/reader035/viewer/2022062309/568159f3550346895dc73f15/html5/thumbnails/23.jpg)
Other TrialNet StudiesOther TrialNet Studies
• Comparison of Mixed Meal Tolerance Test and Glucagon Stimulation Test for Stimulation of C-Peptide
• Reproducibility and Validation of T-Cell Assays for Monitoring of Diabetes Intervention Trials
• Collaboration with Type 1 Diabetes Genetics Consortium (T1DGC)
![Page 24: Natural History of Type 1 Diabetes](https://reader035.vdocuments.site/reader035/viewer/2022062309/568159f3550346895dc73f15/html5/thumbnails/24.jpg)
Key Elements of Successful Key Elements of Successful Clinical TrialsClinical Trials
• Prospective
• Randomized
• Controlled
• Statistical power
• Objective endpoints
• Risk/benefit to individual
• Cost benefit to society
![Page 25: Natural History of Type 1 Diabetes](https://reader035.vdocuments.site/reader035/viewer/2022062309/568159f3550346895dc73f15/html5/thumbnails/25.jpg)
What We NeedWhat We Need
• Proven biomarkers for disease progression or improvement
• Better mechanistic assays• Study designs that involve fewer subjects• Better rationale for moving potential
interventions to RCTs• The courage to study interventions with
potential adverse side effects
![Page 26: Natural History of Type 1 Diabetes](https://reader035.vdocuments.site/reader035/viewer/2022062309/568159f3550346895dc73f15/html5/thumbnails/26.jpg)
![Page 27: Natural History of Type 1 Diabetes](https://reader035.vdocuments.site/reader035/viewer/2022062309/568159f3550346895dc73f15/html5/thumbnails/27.jpg)